Antagonistic bacteria as biopesticides for plant and soil health
A biopesticide platform using antagonistic bacteria and their antimicrobial compounds to combat bacterial, fungal, and oomycete plant pathogens. Validated in plant trials showing significant disease reduction, with potential to improve crop productivity and soil health through environmentally friendly alternatives to chemical pesticides.
Overview
This research program develops biopesticides based on antagonistic bacteria and their bioactive antimicrobial compounds (AMCs) to protect crops from bacterial, fungal, and oomycete pathogens. The work addresses the need for environmentally friendly alternatives to conventional chemical pesticides, with the goal of improving plant health, soil health, and crop productivity.
The platform is grounded in the discovery that microbes from microbe-rich environments have evolved diverse antagonistic interactions that produce novel antimicrobial compounds. A library of more than 600 environmental isolates has been screened, identifying 68 bacteria capable of inhibiting the growth of human, food, and plant pathogens. Coculturing experiments with pathogens yielded 24 crude extracts with confirmed antimicrobial activity, and chemical analysis has so far revealed 29 distinct antimicrobial compounds.
Technical specifications
Discovery and screening pipeline:
- Isolation of bacteria from diverse environmental microbiomes
- Screening against a broad range of plant pathogens, including bacteria, fungi, and oomycetes
- Coculture assays to identify antimicrobial activity
- Chemical characterization of bioactive compounds, including diketopiperazines (DKPs) such as 3-isobutylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione
Validation in plant trials:
- Ten bacteria from the 68-antagonist library were tested as biopesticides
- Pathogens targeted included Pseudomonas syringae, Alternaria brassicicola, and Phytophthora medicaginis
- Trials used five treatments per disease, each with 30 treated and 30 control plants
- Disease symptoms and pathogen counts (measured by Q-PCR) declined significantly (student t-test, p < 0.05) in treated plants
- A mixture of four antagonistic bacteria was also evaluated as a combined biocontrol formulation
Future development priorities:
- Expanded isolation of biocontrol bacteria from additional environmental microbiomes
- Field application against soilborne, airborne, and waterborne plant diseases
- Development of bio-sourced pesticide formulations based on characterized AMCs
- Toxicological and environmental safety assessment of candidate compounds
Technology readiness level
The biopesticide concept has been validated at the laboratory and controlled plant trial stage, with statistically significant reductions in disease symptoms and pathogen load demonstrated across multiple pathogen-host systems. The research team has identified specific antimicrobial compounds, including DKPs, that contribute to the biocontrol activity. Next steps include broader pathogen screening, formulation development for agricultural deployment, and toxicological and environmental safety evaluations required to advance toward field trials and eventual commercialization.
About The University of Queensland
The University of Queensland is a large, multi-campus public research university in Brisbane with a comprehensive academic and research profile. Industry partners engage through hospital-embedded laboratories and clinical sites, pilot testbeds, and field campuses across Queensland that enable prototyping, trials, and validation in real-world settings. Co-location with major health precincts and proximity to Brisbane’s innovation districts make collaboration and talent access straightforward, while on-campus incubation and professional education support workforce upskilling. Research is supported by competitive national funding from the Australian Research Council and the National Health and Medical Research Council, alongside state and industry investment. A dedicated technology transfer office and commercialization company manage IP, licensing, sponsored research agreements, and spin-out formation.
delivered to your inbox.